The burden of human papillomavirus infections and related diseases in sub-saharan Africa

Vaccine

Volumn 31, Issue S5, 2013, Pages

  De Vuyst, Hugo ^a   Alemany, Laia ^b,c   Lacey, Charles ^d   Chibwesha, Carla J ^e,f   Sahasrabuddhe, Vikrant ^g   Banura, Cecily ^h   Denny, Lynette ⁱ   Parham, Groesbeck P ^e  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d UNIVERSITY OF YORK   (United Kingdom)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^g NATIONAL CANCER INSTITUTE   (United States)

^h MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anogenital cancers; Cervical cancer; Genital warts; HPV epidemiology; Sub Saharan Africa

Indexed keywords

AGENTS USED INTRAVAGINALLY; MDP 301; MICROBICIDE; UNCLASSIFIED DRUG;

ANGOLA; ANUS CANCER; BENIN; BOTSWANA; BREAST CANCER; BURKINA FASO; BURUNDI; CAMEROON; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CAPE VERDE; CENTRAL AFRICAN REPUBLIC; CHAD; COMOROS; CONCURRENT SEXUAL PARTNERSHIP; CONDYLOMA ACUMINATUM; CONGO; COTE D'IVOIRE; DJIBOUTI; DNA FINGERPRINTING; EPIDEMIC; EQUATORIAL GUINEA; ERITREA; ETHIOPIA; GABON; GAMBIA; GHANA; GUINEA; GUINEA-BISSAU; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; KENYA; LESOTHO; LIBERIA; LIFE EXPECTANCY; MADAGASCAR; MALAWI; MALI; MAURITANIA; MAURITIUS; MAYOTTE; MEN WHO HAVE SEX WITH MEN; META ANALYSIS (TOPIC); MOZAMBIQUE; NAMIBIA; NIGER; NIGERIA; NONHUMAN; PAPILLOMAVIRUS INFECTION; PENIS CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); POLYGAMY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RWANDA; SAINT HELENA; SENEGAL; SEYCHELLES; SIERRA LEONE; SOCIAL CLASS; SOMALIA; SUDAN; SURVIVAL RATE; SWAZILAND; TANZANIA; TOGO; TUMOR INVASION; UGANDA; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; ZAMBIA; ZIMBABWE; AFRICA SOUTH OF THE SAHARA; ALPHAPAPILLOMAVIRUS; ANUS NEOPLASMS; COMPLICATION; CONDYLOMATA ACUMINATA; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; MALE; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; TOPOGRAPHY; UTERINE CERVICAL NEOPLASMS;

AFRICA SOUTH OF THE SAHARA; ALPHAPAPILLOMAVIRUS; ANUS NEOPLASMS; CONDYLOMATA ACUMINATA; FEMALE; HIV; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; TOPOGRAPHY, MEDICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84890087193     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.092     Document Type: Review

References (97)

1. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in Africa and opportunities for prevention. Cancer 2012 Jan 17. doi: 10.1002/cncr.27410. [Epub ahead of print].
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2010. Lyon, France, International Agency for Research on Cancer. Available at: (last accessed April 2013). http://globocan.iarc.fr/.
3. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publication No. 160. [IX]. 2007. Lyon, IARC.
4. Sankaranarayanan R., Swaminathan R., Brenner H., Chen K., Chia K.S., Chen J.G., et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010, 11:165-173.
5. Parkin D.M., Nambooze S., Wabwire-Mangen F., Wabinga H.R. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer 2010, 126:1187-1195.
6. United Nations Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2008 Revision, Highlights. [2009] Report No;1; ESA/P/WP.210.
7. Bruni L., Diaz M., Castellsagué X., Ferrer E., Bosch F.X., de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
8. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128:927-935.
9. Denny L., Franceschi S., de Sanjosé S., Heard I., Moscicki A.B., Palefsky J. Human papillomavirus, human immune deficiency virus and immunosuppression. Vaccine 2012, 30(Suppl 5). F168-74.
10. Salih M.M., Safi M.E., Hart K., Tobi K., Adam I. Genotypes of human papilloma virus in Sudanese women with cervical pathology. Infect Agent Cancer 2010, 5:26.
11. Keita N., Clifford G.M., Koulibaly M., Douno K., Kabba I., Haba M., et al. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009, 101:202-208.
12. Gage J.C., Ajenifuja K.O., Wentzensen N.A., Adepiti A.C., Eklund C., Reilly M., et al. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen-and-treat strategies. Int J Cancer 2012, 130:2111-2117.
13. Thomas J.O., Herrero R., Omigbodun A.A., Ojemakinde K., Ajayi I.O., Fawole A., et al. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004, 90:638-645.
14. Schnatz P.F., Markelova N.V., Holmes D., Mandavilli S.R., O'Sullivan D.M. The prevalence of cervical HPV and cytological abnormalities in association with reproductive factors of rural Nigerian women. J Womens Health (Larchmt) 2008, 17:279-285.
15. Naucler P., Mabota da Costa F., da Costa J.L., Ljungberg O., Bugalho A., Dillner J. Human papillomavirus type-specific risk of cervical cancer in a population with high human immunodeficiency virus prevalence: case-control study. J Gen Virol 2011, 92(Pt 12):2784-2791.
16. Wright T.C., Denny L., Kuhn L., Pollack A., Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000, 283:81-86.
17. Allan B., Marais D.J., Hoffman M., Shapiro S., Williamson A.L. Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J Clin Microbiol 2008, 46:740-742.
18. Sangwa-Lugoma G., Ramanakumar A.V., Mahmud S., Liaras J., Kayembe P.K., Tozin R.R., et al. Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-Saharan African community. Sex Transm Dis 2011, 38:308-315.
19. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective, International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802.
20. Vidal A.C., Murphy S.K., Hernandez B.Y., Vasquez B., Bartlett J.A., Oneko O., et al. Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. Infect Agent Cancer 2011, 6:20.
21. Williamson A.L., Brink N.S., Dehaeck C.M., Ovens S., Soeters R., Rybicki E.P. Typing of human papillomaviruses in cervical carcinoma biopsies from Cape Town. J Med Virol 1994, 43:231-237.
22. Kay P., Soeters R., Nevin J., Denny L., Dehaeck C.M., Williamson A.L. High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia. J Med Virol 2003, 71:265-273.
23. Muwogue C, Musana O, Othieno E, GGayi A, Levin J, Hugues P, et al. The spectrum of HPV genotypes in cervical cancer in Uganda [Poster]. Presented at the 26th International Papillomavirus Conference and Clinical Workshop. 03-08 July 2010. Montreal, Canada. Presentation P-620.
24. Schmidt J, Adewole I, Anorlu R, Moodley M, Smith T, Wiredu E, et al. HPV type distribution in invasive cervical cancer in Sub-Saharan Africa [Abstract]. Presented at the 27th International Papillomavirus Conference and Clinical Workshop. 17-22 September 2011. Berlin Germany. Presentation P-32-39.
25. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjosé S., Franceschi S., et al. Human papillomavirus (HPV) types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131:2349-2359.
26. de Sanjosé S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
27. Bekele A., Baay M., Mekonnen Z., Suleman S., Chatterjee S. Human papillomavirus type distribution among women with cervical pathology - a study over 4 years at Jimma Hospital, southwest Ethiopia. Trop Med Int Health 2010, 15:890-893.
28. De Vuyst H., Ndirangu G., Moodley M., Tenet V., Estambale B., Meijer C.J., et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer 2012, 131:949-955.
29. Naucler P., Da Costa F.M., Ljungberg O., Bugalho A., Dillner J. Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol 2004, 85(Pt 8):2189-2190.
30. De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
31. Miralles-Guri C., Bruni L., Cubilla A.L., Castellsagué X., Bosch F.X., de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62:870-878.
32. Insinga R.P., Liaw K.L., Johnson L.G., Madeleine M.M. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008, 17:1611-1622.
33. Ng'ayo M.O., Bukusi E., Rowhani-Rahbar A., Koutsky L.A., Feng Q., Kwena Z.A., et al. Epidemiology of human papillomavirus infection among fishermen along Lake Victoria Shore in the Kisumu District, Kenya. Sex Transm Infect 2008, 84:62-66.
34. Smith J.S., Backes D.M., Hudgens M.G., Bailey R.C., Veronesi G., Bogaarts M., et al. Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. Int J Cancer 2010, 126:572-577.
35. Tobian A.A., Serwadda D., Quinn T.C., Kigozi G., Gravitt P.E., Laeyendecker O., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009, 360:1298-1309.
36. Tobian A.A., Kong X., Gravitt P.E., Eaton K.P., Kigozi G., Serwadda D., et al. Male circumcision and anatomic sites of penile high-risk human papillomavirus in Rakai, Uganda. Int J Cancer 2011, 129:2970-2975.
37. Auvert B., Sobngwi-Tambekou J., Cutler E., Nieuwoudt M., Lissouba P., Puren A., et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009, 199:14-19.
38. Wawer M.J., Tobian A.A., Kigozi G., Kong X., Gravitt P.E., Serwadda D., et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet 2011, 377(9761):209-218.
39. Rubin M.A., Kleter B., Zhou M., Ayala G., Cubilla A.L., Quint W.G., et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001, 159:1211-1218.
40. Daling J.R., Madeleine M.M., Johnson L.G., Schwartz S.M., Shera K.A., Wurscher M.A., et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 2005, 116:606-616.
41. Picconi M.A., Eijan A.M., Distefano A.L., Pueyo S., Alonio L.V., Gorostidi S., et al. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol 2000, 61:65-69.
42. Senba M., Kumatori A., Fujita S., Jutavijittum P., Yousukh A., Moriuchi T., et al. The prevalence of human papillomavirus genotypes in penile cancers from northern Thailand. J Med Virol 2006, 78:1341-1346.
43. Tornesello M.L., Duraturo M.L., Guida V., Losito S., Botti G., Pilotti S., et al. Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma. Cancer Lett 2008, 269:159-164.
44. Senba M., Buziba N., Mori N., Wada A., Irie S., Toriyama K. Detection of Human papillomavirus and cellular regulators p16INK4a, p53, and NF-kappaB in penile cancer cases in Kenya. Acta Virol 2009, 53:43-48.
45. Latif A.S. Sexually, transmitted disease in clinic patients in Salisbury, Zimbabwe. Br J Vener Dis 1981, 57:181-183.
46. Schmauz R, Owor R. Epidemiological aspects of cervical cancer in tropical Africa. IARC Sci Publ 1984;(63):413-31.
47. Firnhaber C., Sello M., Maskew M., Williams S., Schulze D., Williamson A.L., et al. Human papillomavirus types in HIV seropositive men with penile warts in Johannesburg, South Africa. Int J STD AIDS 2011, 22:107-109.
48. McCormack S., Ramjee G., Kamali A., Rees H., Crook A.M., Gafos M., et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010, 376(9749):1329-1337.
49. Low A.J., Clayton T., Konate I., Nagot N., Ouedraogo A., Huet C., et al. Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. BMC Infect Dis 2011, 11:20.
50. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87:544-547.
51. Guimaraes M.D., Grinsztejn B., Melo V.H., Rocha G.M., Campos L.N., Pilotto J.H., et al. Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil. J Acquir Immune Defic Syndr 2011, 57(Suppl 3):S217-S224.
52. Kojic E.M., Cu-Uvin S., Conley L., Bush T., Onyekwuluje J., Swan D.C., et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis 2011, 38:253-259.
53. Smith J.S., Moses S., Hudgens M.G., Parker C.B., Agot K., Maclean I., et al. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis 2010, 201:1677-1685.
54. Smith-McCune K.K., Shiboski S., Chirenje M.Z., Magure T., Tuveson J., Ma Y., et al. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One 2010, 5:e10094.
55. Clifford G.M., Goncalves M.A., Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006, 20:2337-2344.
56. Sahasrabuddhe V.V., Mwanahamuntu M.H., Vermund S.H., Huh W.K., Lyon M.D., Stringer J.S., et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007, 96:1480-1483.
57. Strickler H.D., Palefsky J.M., Burk R.D. HPV types present in invasive cervical cancers of HIV-seropositive women. Int J Cancer 2008, 123:1224-1225.
58. Broker T.R., Jin G., Croom-Rivers A., Bragg S.M., Richardson M., Chow L.T., et al. Viral latency--the papillomavirus model. Dev Biol (Basel) 2001, 106:443-451.
59. WHO. Global HIV/AIDS response; Progress report 2011. Available at:. http://www.who.int/hiv/pub/progress_report2011/regional_facts/en/index.html.
60. Franceschi S., Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis 2007, 45:510-513.
61. Grulich A.E., Jin F., Conway E.L., Stein A.N., Hocking J. Cancers attributable to human papillomavirus infection. Sex Health 2010, 7:244-252.
62. Bratcher L.F., Sahasrabuddhe V.V. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 2010, 5:8.
63. Czoski-Murray C., Karnon J., Jones R., Smith K., Kinghorn G. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010, 14:iii-x. 1.
64. Palefsky J.M. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010, 46(4 Suppl):S12-S19.
65. Minkoff H., Zhong Y., Burk R.D., Palefsky J.M., Xue X., Watts D.H., et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010, 201:681-690.
66. Mah T.L., Halperin D.T. Concurrent sexual partnerships and the HIV epidemics in Africa: evidence to move forward. AIDS Behav 2010, 14:11-16.
67. Lurie M.N., Rosenthal S. Concurrent partnerships as a driver of the HIV Epidemic in sub-Saharan Africa. The evidence is limited. AIDS Behav 2010, 14:17-24.
68. Tanser F., Barnighausen T., Hund L., Garnett G.P., McGrath N., Newell M.L. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet 2011, 378(9787):247-255.
69. UN High Commissioner for Refugees. Trends in Displacement, Protection and Solutions: Ten Years of Statistics. 2011. Available at: (last accessed April 2013). http://www.unhcr.org/.
70. Rubenstein L.S. Post-conflict health reconstruction: search for a policy. Disasters 2011, 35:680-700.
71. Pavignani E. Human resources for health through conflict and recovery: lessons from African countries. Disasters 2011, 35:661-679.
72. Cottingham J., Garcia-Moreno C., Reis C. Sexual and reproductive health in conflict areas: the imperative to address violence against women. BJOG 2008, 115:301-303.
73. Kivlahan C., Ewigman N. Rape as a weapon of war in modern conflicts. BMJ 2010, 340:c3270.
74. Spiegel P.B., Checchi F., Colombo S., Paik E. Health-care needs of people affected by conflict: future trends and changing frameworks. Lancet 2010, 375(9711):341-345.
75. Piras F., Piga M., De M.A., Zannou A.R., Minerba L., Perra M.T., et al. Prevalence of human papillomavirus infection in women in Benin, West Africa. Virol J 2011, 8:514.
76. La Ruche G., You B., Mensah-Ado I., Bergeron C., Montcho C., Ramon R., et al. Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia-neoplasia in African women. Int J Cancer 1998, 76:480-486.
77. Adjorlolo-Johnson G., Unger E.R., Boni-Ouattara E., Toure-Coulibaly K., Maurice C., Vernon S.D., et al. Assessing the relationship between HIV infection and cervical cancer in Cote d'Ivoire: a case-control study. BMC Infect Dis 2010, 10:242.
78. Wall S.R., Scherf C.F., Morison L., Hart K.W., West B., Ekpo G., et al. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 2005, 93:1068-1076.
79. Tracy J.K., Traore C.B., Bakarou K., Dembele R., Coulibaly R.C., Sow S.O. Risk factors for high-risk human papillomavirus infection in unscreened Malian women. Trop Med Int Health. 2011, 16:1432-1438.
80. Astori G., Beltrame A., Pipan C., Raphenon G., Botta G.A. PCR-RFLP-detected human papilloma virus infection in a group of senegalese women attending an STD clinic and identification of a new HPV-68 subtype. Intervirology 1999, 42:221-227.
81. Xi L.F., Toure P., Critchlow C.W., Hawes S.E., Dembele B., Sow P.S., et al. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 2003, 103:803-809.
82. De Vuyst H., Steyaert S., Van Renterghem L., Claeys P., Muchiri L., Sitati S., et al. Distribution of human papillomavirus in a family planning population in Nairobi, Kenya. Sex Transm Dis 2003, 30:137-142.
83. De Vuyst H., Parisi M.R., Karani A., Mandaliya K., Muchiri L., Vaccarella S., et al. The prevalence of human papillomavirus infection in Mombasa, Kenya. Cancer Causes Control 2010, 21:2309-2313.
84. Castellsagué X., Menendez C., Loscertales M.P., Kornegay J.R., dos Santos F., Gomez-Olive F.X., et al. Human papillomavirus genotypes in rural Mozambique. Lancet 2001, 358(9291):1429-1430.
85. Odida M., Sandin S., Mirembe F., Kleter B., Quint W., Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study. Infect Agent Cancer 2011, 6:8.
86. Womack S.D., Chirenje Z.M., Gaffikin L., Blumenthal P.D., McGrath J.A., Chipato T., et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000, 85:206-210.
87. Jones H.E., Allan B.R., van de Wijgert J.H., Altini L., Taylor S.M., de Kock A., et al. Agreement between self- and clinician-collected specimen results for detection and typing of high-risk human papillomavirus in specimens from women in Gugulethu, South Africa. J Clin Microbiol 2007, 45:1679-1683.
88. Bayo S., Bosch F.X., de Sanjosé S., Muñoz N., Combita A.L., Coursaget P., et al. Risk factors of invasive cervical cancer in Mali. Int J Epidemiol 2002, 31:202-209.
89. Okolo C., Franceschi S., Adewole I., Thomas J.O., Follen M., Snijders P.J., et al. Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infect Agent Cancer 2010, 5:24.
90. Lin P., Koutsky L.A., Critchlow C.W., Apple R.J., Hawes S.E., Hughes J.P., et al. HLA class II DR-DQ and increased risk of cervical cancer among Senegalese women. Cancer Epidemiol Biomarkers Prev 2001, 10:1037-1045.
91. Fanta B.E. The distribution of Human Papilloma Virus infection in women with cervical histological abnormalities from an area with high incidence of cervical cancer. Ethiop Med J 2005, 43:151-158.
92. De Vuyst H., Gichangi P., Estambale B., Njuguna E., Franceschi S., Temmerman M. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer 2008, 122:244-246.
93. Castellsagué X., Klaustermeier J., Carrilho C., Albero G., Sacarlal J., Quint W., et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int J Cancer 2008, 122:1901-1904.
94. ter Meulen J., Eberhardt H.C., Luande J., Mgaya H.N., Chang-Claude J., Mtiro H., et al. Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa. Int J Cancer 1992, 51:515-521.
95. Odida M., de Sanjosé S., Quint W., Bosch X.F., Klaustermeier J., Weiderpass E. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis 2008, 8:85.
96. Stanczuk G.A., Kay P., Sibanda E., Allan B., Chirara M., Tswana S.A., et al. Typing of human papillomavirus in Zimbabwean patients with invasive cancer of the uterine cervix. Acta Obstet Gynecol Scand 2003, 82:762-766.
97. Pegoraro R.J., Rom L., Lanning P.A., Moodley M., Naiker S., Moodley J. P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer 2002, 12:383-388.